Onychomysosis
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Eekanna ika ẹsẹ kan ti o kan Onychomysosis
Ẹsẹ eniyan ti o ni arun eekanna olu ọsẹ mẹwa sinu ilana ti oogun ẹnu terbinafine. Ṣe akiyesi ẹgbẹ ti idagbasoke eekanna ilera lẹhin awọn eekanna ti o ni arun ti o ku.
References
Awọn antifungals eto eto jẹ itọju ti o munadoko julọ. Awọn itupalẹ-meta ṣe afihan awọn oṣuwọn imularada mycotic gẹgẹbi atẹle: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Iyọkuro eekanna concomitant siwaju sii mu awọn oṣuwọn imularada pọ si. Itọju ailera pẹlu ciclopirox ko munadoko; o ni oṣuwọn ikuna ti o kọja 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onychomycosis jẹ akoran olu ti o ni ipa lori eekanna. Nigba ti o ṣẹlẹ nipasẹ awọn dermatophytes, a npe ni tinea unguium. Onychomycosis pẹlu awọn akoran ti o fa nipasẹ dermatophytes, iwukara, ati m. Iṣoro eekanna ti a ko fa nipasẹ akoran olu ni a npe ni nail dystrophy. Botilẹjẹpe o le ni ipa lori eekanna ika ati ika ẹsẹ, onychomycosis toenail jẹ wọpọ julọ. Nkan yii jiroro lori ọpọlọpọ awọn aaye ti onychomycosis ika ẹsẹ, gẹgẹbi ipa rẹ, awọn iru ile-iwosan, awọn ipele, iwadii aisan, ati itọju. Lakoko ti kii ṣe idẹruba igbesi aye, onychomycosis le ja si awọn ilolu to ṣe pataki bi cellulitis, sepsis, ikolu egungun, ibajẹ ara, ati isonu eekanna.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine jẹ oogun kan ti o koju awọn akoran olu nipa didi squalene epoxidase. O munadoko lodi si ọpọlọpọ awọn oriṣi ti elu ara ati pe o fọwọsi fun atọju fungus eekanna nigbati o ba mu ni ẹnu. Lakoko ti ọpọlọpọ awọn ipa ẹgbẹ bi awọn efori ati awọn ọran ikun jẹ kekere ati lọ si ara wọn, awọn iyipada ninu itọwo (dysgeusia) le yatọ lati ìwọnba si àìdá, nigbakan ti o yori si pipadanu iwuwo. Awọn iyipada itọwo to yẹ jẹ toje ṣugbọn ti royin.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onychomycosis jẹ akoran olu ti o ni ipa lori eekanna. Ni ayika 90% awọn akoran eekanna ika ẹsẹ ati 75% awọn akoran eekanna ika ni o fa nipasẹ elu (Trichophyton mentagrophytes, Trichophyton rubrum) . Awọn aami aisan pẹlu iyipada eekanna, nipọn, ipinya lati ibusun àlàfo, ati idagbasoke pupọ. Itọju jẹ igbagbogbo pẹlu awọn oogun ẹnu bi terbinafine tabi itraconazole, pẹlu awọn itọju ti agbegbe jẹ aṣayan fun awọn ọran kekere si iwọntunwọnsi.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Oogun antifungal terbinafine ti a mu nipasẹ ẹnu dabi ẹni pe o munadoko julọ ṣugbọn terbinafine ni nkan ṣe pẹlu ipa ẹgbẹ ti ẹdọ.
Onychomysosis waye ni iwọn 10 ogorun ti olugbe agbalagba, pẹlu awọn agbalagba ti o ni ipa nigbagbogbo. Awọn ọkunrin ni o ni ipa diẹ sii ju awọn obinrin lọ. Onychomysosis duro fun bii idaji arun eekanna. Eyi tumọ si pe idibajẹ ti awọn eekanna ika ẹsẹ le tun wa lati awọn okunfa miiran ju onychomycosis.
○ Itọju - Oògùn OTC
O nira lati tọju onychomycosis pẹlu awọn oogun ti agbegbe nitori pe o ṣoro fun awọn oogun lati wọ awọn eekanna ika ẹsẹ ti o nipọn.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Itọju
Itọju igba pipẹ ni a nilo nigbagbogbo titi ti eekanna ika ẹsẹ ti o ni arun yoo fi yọ kuro patapata.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer